Yervoy  (ipilimumab) – a monoclonal antibody for the treatment of patients with unresectable (inoperable) or metastatic melanoma  Orencia  – a fusion protein indicated for rheumatoid arthritis (RA)  Nulojix  (belatacept) – a fusion protein with novel immunosuppressive activity for the prevention of kidney transplant rejection  Onglyza/Kombiglyze  (saxagliptin/once daily combination of saxagliptin and metformin hydrochloride extended-release) – a treatment  for type 2 diabetes that is part of our strategic alliance with AstraZeneca  6 In addition, in August 2012, the Company discontinued development of BMS-986094. This decision was made in the interest of  patient safety. See Note 13 “Goodwill and Other Intangible Assets” for further information.  Bristol-Myers Squibb  • In November 2012, the National Institute of Health and Clinical Excellence (NICE) recommended  Yervoy , which is approved in  the EU for the treatment for previously, treated metastatic (advanced) melanoma, within the Final Appraisal Determination. This  important recommendation will enable eligible patients in England and Wales to routinely access treatment with  Yervoy  through  the National Health Services.  • In September 2012, the Company announced at the European Society for Medical Oncology 2012 Congress long-term follow-up  data of the 024 study which evaluated newly-diagnosed patients treated with  Yervoy  10mg/kg in combination with dacarbazine  versus dacarbazine alone and five-year follow-up data from the rollover 025 study which evaluated patients with  Yervoy  0.3  mg/kg or 10 mg/kg. The survival rates observed in study 024 at years three and four were not only stable but higher in patients  treated with  Yervoy  plus dacarbazine versus patients who received dacarbazine alone. The estimated survival rates in the 025  study remained unchanged or relatively stable at five years compared to four years in newly-diagnosed patients and previously- diagnosed patients.  • In October 2012, the EC granted marketing authorization for a subcutaneous formulation of  Orencia  in combination with  methotrexate for the treatment of moderate to severe active RA in adults.  • In June 2012, at the European League Against Rheumatism Annual European Congress of Rheumatology, the Company  announced that AMPLE, a head-to-head trial of 646 patients comparing the subcutaneous formulation of  Orencia  vs.  Humira (adalimumab), each on a background of methotrexate (MTX), in biologic naïve patients with moderate to severe RA met its  primary endpoint (as measured by non-inferiority) demonstrating that  Orencia  plus MTX achieved comparable rates of efficacy  for the American College of Rheumatology criteria of 20 percent (ACR 20) response at one year of 64.8% vs. 63.4%  Humira  plus  MTX.  • In May 2012, the Company announced that the FDA had approved the Company’s biologics manufacturing facility in Devens,  Massachusetts for commercial production of  Orencia .  • In June 2012, at the 2012 American Transplant Congress, the Company announced new four-year results from the long-term  extensions (LTE) of the BENEFIT and BENEFIT-EXT clinical trials of  Nulojix , the first T-cell costimulation blocker indicated  for the prophylaxis of organ rejection in adult Epstein-Barr Virus seropositive patients receiving a kidney transplant, in  combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. Results showed that the safety profile of  Nulojix  through year four was consistent compared with results at year three with no new safety signals being identified, and that  the renal function benefit versus cyclosporine was maintained through four years in patients enrolled in the LTE from both the  BENEFIT and BENEFIT-EXT trials.  • In July 2012, the Company and AstraZeneca announced at the 17$^{th}$ World Congress on Heart Disease the results of analyses  showing that  Onglyza  5mg demonstrated improvements across key measures of blood sugar control (glycosylated hemoglobin  levels, or HbA1c; fasting plasma glucose, or FPG and post-prandial glucose, or PPG) compared to placebo in adult patients with  type 2 diabetes at high risk for cardiovascular disease.